R&D Solutions
Capabilities
Helping biopharma companies focus on the patient
A Life Sciences industry leader
New Science is driving biopharma growth
54%
of sales between 2017 and 2022 are expected to be driven by New Science, up from 47% between 2012 and 2017.
6-7x
more investment is being made in digital, data and genomics by leaders in New Science compared to their peers.
50%
higher Probability of Technical and Regulatory Success (PTRS) with New Science compared to other treatments.
Our events
What we think
Our leaders
Thomas Lehmann
Accenture US Life Sciences Consulting and Americas Life Sciences Industry Lead